STACK DAVID M
Known title: CEO and ChairmanCIK: 0001204788
Associated companies
Transaction History
| PCRX | ▲ Buy | Grant | 32,700 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,326 | $202K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,058 | $197K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,039 | $416K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,006 | $302K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,282 | $79K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 501 | $31K | 6/8/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 21,500 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 11,965 | $734K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 22,500 | $243K | 4/28/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 22,500 | $243K | 3/31/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 13,670 | $148K | 1/25/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 15,000 | $162K | 1/11/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 15,000 | $162K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.